RBCL — RBC Life Sciences Share Price
Last trade - 00:00- $0.00m
- -$2.09m
- $28.27m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0 | ||
| Price to Tang. Book | 0 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -7.1% | ||
| Return on Equity | -6.77% | ||
| Operating Margin | -2.52% | ||
Financial Summary
| Year End 31st Dec | Unit | 2010 | 2011 | 2012 | 2013 | 2014 | 2015E | 2016E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 28.16 | 28.45 | 25.16 | 25.47 | 28.27 | n/a | n/a | 2.55% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
RBC Life Sciences, Inc. is engaged in the marketing of nutritional supplements and personal care products through subsidiaries in North America and Southeast Asia and through licensees in Russia/Eastern Europe. The Company's segments include Nutritional Products and Medical Products. Its Nutritional Products segment distributes products in over three categories: wellness products, fitness products and personal care products. Its Medical Products segment distributes wound care products. Nutritional Products are marketed under the RBC Life brand name. As of September 30, 2015, its Nutritional Products segment manufactured and distributed a line of over 100 nutritional supplements and personal care products, including herbs, vitamins and minerals, as well as natural skin, hair and body care products. As of September 30, 2015, it marketed a line of over 35 wound care products under the MPM Medical brand name through a subsidiary operating primarily in the United States.
Directors
- Clinton Howard CHM (86)
- Steven Brown PRE (59)
- Douglas Wheeler VOP (41)
- Barton Dangerfield VPR (54)
- Daley Seeker SEC (28)
- Andrew Howard DRC (56)
- Joseph Philipp IND (65)
- Cynthia Tysinger IND (57)
- Last Annual
- December 31st, 2014
- Last Interim
- September 30th, 2015
- Incorporated
- October 4th, 1999
- Public Since
- March 27th, 1996
- No. of Employees
- 76
- Sector
- Specialty Retailers
- Industry
- Consumer Cyclicals
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 2,213,010
- Address
- 2301 Crown Ct, IRVING, 75038-4305
- Web
- https://www.rbclifesciences.com/
- Phone
- +1 9728934000
- Auditors
- Lane- Gorman- Trubitt & Co.
Similar to RBCL
Arion
Pink Sheets on Nasdaq
Avolta AG
Pink Sheets on Nasdaq
bebe stores
Pink Sheets on Nasdaq
Better for You Wellness
Pink Sheets on Nasdaq
BioForce Nanosciences Holdings
Pink Sheets on Nasdaq
FAQ
As of Today at 19:17 UTC, shares in RBC Life Sciences are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in RBC Life Sciences last closed at $0.00 and the price had moved by -99.48% over the past 365 days. In terms of relative price strength the RBC Life Sciences share price has underperformed the S&P500 Index by -99.55% over the past year.
There is no consensus recommendation for this security.
RBC Life Sciences does not currently pay a dividend.
RBC Life Sciences does not currently pay a dividend.
RBC Life Sciences does not currently pay a dividend.
To buy shares in RBC Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in RBC Life Sciences had a market capitalisation of $0.00m.
Here are the trading details for RBC Life Sciences:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: RBCL
Based on an overall assessment of its quality, value and momentum RBC Life Sciences is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like RBC Life Sciences. Over the past six months, its share price has underperformed the S&P500 Index by -80.75%.
As of the last closing price of $0.00, shares in RBC Life Sciences were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The RBC Life Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
RBC Life Sciences' management team is headed by:
- Clinton Howard - CHM
- Steven Brown - PRE
- Douglas Wheeler - VOP
- Barton Dangerfield - VPR
- Daley Seeker - SEC
- Andrew Howard - DRC
- Joseph Philipp - IND
- Cynthia Tysinger - IND